MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer

  • Karina E. Hew
  • , Philip C. Miller
  • , Dorraya El-Ashry
  • , Jun Sun
  • , Alexandra H. Besser
  • , Tan A. Ince
  • , Mengnan Gu
  • , Zhi Wei
  • , Gao Zhang
  • , Patricia Brafford
  • , Wei Gao
  • , Yiling Lu
  • , Gordon B. Mills
  • , Joyce M. Slingerland
  • , Fiona Simpkins

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Fingerprint

Dive into the research topics of 'MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology